Another round of disappointing data for NGD 2000-1 caused Neurogen Corp.'s stock to drop nearly 19 percent Wednesday, and made further development of the product in rheumatoid arthritis an unlikely plan. (BioWorld Today)

In a transaction valued at $855 million, QLT Inc. and Atrix Laboratories Inc. are merging into a single entity with two marketed products and a multitude of pipeline possibilities. (BioWorld Today)

Tissue-regeneration company Isolagen Inc. brought in $59.5 million in a follow-on offering Thursday, leaving it with wrinkle-free plans to begin pivotal trials and bring its lead anti-aging product to the market. (BioWorld Today)

As it transforms itself from a genomics discovery company to a product development company, CuraGen Corp. in-licensed a promising cancer compound from the Danish firm TopoTarget A/S. (BioWorld Today)

In spite of an FDA panel's recommendation against Allos Therapeutics Inc.'s RSR13, the agency issued an approvable letter for the radiation sensitizer. (BioWorld Today)